Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Renal Recovery Patterns and Long-Term Kidney Function Decline in Pulmonary Hypertension.

Pulmonary circulation·2026
Same author

Spatial proteomics profiling reveals oncogene-specific immune niches and prognostic markers in NSCLC.

American journal of respiratory and critical care medicine·2026
Same author

IRG1/itaconate rewires macrophage and lung tumor metabolism through G6PD inhibition.

Cell metabolism·2026
Same author

Diagnostic yield and histopathological assessment of endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy: a prospective comparison of two tunnelling approaches.

ERJ open research·2026
Same author

Circulating Biomarker Results From a Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension.

American journal of respiratory and critical care medicine·2026
Same author

Case Report: Tezepelumab as rescue therapy in near-fatal asthma requiring extracorporeal membrane oxygenation.

Frontiers in immunology·2026

Related Experiment Video

Updated: Jun 27, 2026

Measurement of Cyclic Guanosine Monophosphate (cGMP) in Solid Tissues using Competitive Enzyme-Linked Immunosorbent Assay (ELISA)
07:15

Measurement of Cyclic Guanosine Monophosphate (cGMP) in Solid Tissues using Competitive Enzyme-Linked Immunosorbent Assay (ELISA)

Published on: July 3, 2025

Modulating cGMP to treat lung diseases.

Hossein-Ardeschir Ghofrani1, Friedrich Grimminger

  • 1University Hospital Giessen and Marburg GmbH, Klinikstrasse 36, Giessen, 35392, Germany. ardeschir.ghofrani@innere.med.uni-giessen.de

Handbook of Experimental Pharmacology
|December 18, 2008
PubMed
Summary

Nitric oxide (NO) regulates lung perfusion. Phosphodiesterase (PDE) inhibitors stabilize cyclic nucleotides, impacting NO signaling pathways. New stimulators of soluble guanylate cyclase (sGC) show therapeutic promise for lung vascular disorders.

More Related Videos

Establishment of a Mouse Model with Cough Hypersensitivity via Inhalation of Citric Acid
05:43

Establishment of a Mouse Model with Cough Hypersensitivity via Inhalation of Citric Acid

Published on: January 10, 2025

Related Experiment Videos

Last Updated: Jun 27, 2026

Measurement of Cyclic Guanosine Monophosphate (cGMP) in Solid Tissues using Competitive Enzyme-Linked Immunosorbent Assay (ELISA)
07:15

Measurement of Cyclic Guanosine Monophosphate (cGMP) in Solid Tissues using Competitive Enzyme-Linked Immunosorbent Assay (ELISA)

Published on: July 3, 2025

Establishment of a Mouse Model with Cough Hypersensitivity via Inhalation of Citric Acid
05:43

Establishment of a Mouse Model with Cough Hypersensitivity via Inhalation of Citric Acid

Published on: January 10, 2025

Area of Science:

  • Pulmonary Medicine
  • Biochemistry
  • Pharmacology

Background:

  • Nitric oxide (NO) is produced in the lung by NO-synthases in vascular endothelium and airway epithelia.
  • NO regulates pulmonary perfusion by optimizing ventilation/perfusion distribution.
  • NO-synthase activity is modulated transcriptionally and post-translationally.
  • Cyclic nucleotides (cAMP, cGMP) mediate signaling for vasodilators like NO.
  • Phosphodiesterases (PDEs) inactivate cAMP and cGMP, with inhibitors affecting these cyclic nucleotide levels.

Purpose of the Study:

  • To explore the role of NO in lung physiology.
  • To investigate the mechanism of action of PDE inhibitors.
  • To evaluate novel therapeutic strategies for lung vascular disorders.

Main Methods:

  • Review of NO-synthase regulation.
  • Analysis of cyclic nucleotide signaling pathways.
  • Examination of PDE enzyme families and their substrates.
  • Discussion of emerging sGC activators and stimulators.

Main Results:

  • NO is crucial for regulating pulmonary perfusion.
  • PDE inhibitors offer a way to modulate cAMP and cGMP levels.
  • Soluble guanylate cyclase (sGC) activators present a promising therapeutic avenue.
  • sGC stimulators may offer greater potency than PDE inhibitors or exogenous NO.

Conclusions:

  • NO signaling is a key target for lung vascular disease treatment.
  • Modulating cyclic nucleotide pathways via PDE inhibition or sGC stimulation offers therapeutic potential.
  • Emerging sGC activators represent a significant advancement in treating lung vascular disorders.